XML 106 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Shareholders' Equity
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Shareholders' Equity Shareholders' Equity
Dividends
For the three months ended March 31, 2025, and 2024, the Company declared quarterly dividends on our common stock totaling approximately $8.2 million and $7.3 million, respectively.
Share-Based Compensation
The Company's stockholders approved the Amended and Restated 2021 Long Term Incentive Plan (the "A&R LTIP") which authorizes up to 2,337,022 shares of common stock that may be granted as awards under the A&R LTIP. In March 2025, the Company introduced performance-based restricted stock awards (the "2025 Executive Performance Shares") in addition to time-based restricted stock awards to further align the compensation of the Company's executive officers with the long-term growth and the interests of its shareholders. Performance-based restricted stock awards represent 30% of total executive award value and may be earned based on the Company’s achievement of total shareholder return (“TSR”) relative to its peer group during the applicable three-year performance period. Payouts for the executive officers can range from 0% to 200% of the target and have cliff-vesting after three years. As a result, the Company has reduced the remaining shares available to be granted as awards under the A&R LTIP by 168,406 shares (the full 200%), which assumes the highest percentage payout for the performance-based restricted stock awards. As of March 31, 2025, the A&R LTIP had 516,375 shares remaining that are available for future awards.
2021 Long-Term Incentive Plan
The following table presents the Company's restricted stock activity during the three months ended March 31, 2025, under the A&R LTIP:
Amended and Restated 2021 Long-Term Incentive Plan
Restricted SharesWeighted Average Grant Date Fair Value
Unvested at December 31, 2024
387,915 $26.57 
Granted 455,755 $30.57 
Vested (18,508)$28.32 
Forfeited(6,311)$27.31 
Unvested at March 31, 2025
818,851 $28.75 
For the three months ended March 31, 2025, and 2024, the total share-based compensation expense was $1.4 million and $1.7 million, respectively. Share-based compensation expense is included in general and administrative costs in the Company's accompanying condensed consolidated statements of operations for the restricted share awards granted under the A&R LTIP. Approximately $21.4 million of additional share-based compensation expense will be recognized over the weighted average life of 31 months for the unvested restricted share awards as of March 31, 2025.
At-The-Market Equity Sales Program
The Company's Equity Distribution Agreement in connection with an ATM allows the Company to offer and sell from time to time up to an aggregate $50 million in shares of the Company's common stock through our agents. During the three months ended March 31, 2025, the Company did not execute any sales under the ATM program. As of March 31, 2025, the Company had remaining capacity to sell up to an additional $49.7 million of common stock under the ATM program.
2024 Equity Offering
On April 8, 2024, the Company issued and sold 1,015,000 shares of common stock at a price of $27.00 per share. Net proceeds from the 2024 Equity Offering were approximately $25.4 million, after deducting underwriting discounts and commissions and expenses. The proceeds were used for financing an acquisition, repayment of outstanding debt and general corporate purposes.